News

4 UCSF Faculty Elected to American Academy of Arts and Sciences' 2015 Class

Frank McCormick, Robert Nussbaum and James Wells are Helen Diller Family Comprehensive Cancer Center members. Renowned UC San Francisco pioneers in cancer, biochemistry, medical genetics and pharmaceutical sciences have been elected as members of the American Academy of Arts and Sciences, which

UCSF joins lung cancer dream team

Previous HDFCCC director and long-time RAS researcher Frank McCormick will join a group of prominent cancer research and treatment institutions in a new Stand Up To Cancer (SU2C)-American Cancer Society $20 million Dream Team to combat lung cancer. Stand Up To Cancer (SU2C) and the American Cancer

Rena Pasick: Changing the Face of Population Science & Public Health

When Rena Pasick joined UCSF in 2002, she brought a key program: the Minority Training Program in Cancer Control Research (MTPCCR) with sites here and at UCLA. With funding from a National Cancer Institute training grant through 2018, her program encourages and supports underrepresented master’s

Angiogenesis Inhibitors Undermined by Immune Cells, Says Study

Angiogenesis inhibitors—a widely used class of cancer drugs designed to shrink tumors by preventing them from forming new blood vessels—often work in the short term, but usually become ineffective within months. Now, a team led by UC San Francisco scientists has discovered a possible reason, one

California Launches Initiative to Advance Precision Medicine

Gov. Jerry Brown is launching a statewide initiative with the University of California, to advance the field of precision medicine. The effort will involve collaborating with other academic and industry partners and starting to build the infrastructure and assemble the resources necessary to further

Dual Therapy's One-Two Punch Knocks Out Drug-Resistant Lung Cancer

Capitalizing on a rare opportunity to thoroughly analyze a tumor from a lung cancer patient who had developed resistance to targeted drug treatment, UC San Francisco scientists identified a biological escape hatch that explains the resistance, and developed a strategy in mice for shutting it down

Immunotherapy: A Field Whose Day Has Come

In closing the 2015 UCSF Helen Diller Family Comprehensive Cancer Center Symposium, President Alan Ashworth, PhD, FRS, counted himself among those who might once have underappreciated the full potential of cancer immunotherapy. “But,” he declared, “it is clearly a field whose day has come.” He also